Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

A novel inflammatory role for platelets in sickle cell disease.

Davila J, Manwani D, Vasovic L, Avanzi M, Uehlinger J, Ireland K, Mitchell WB.

Platelets. 2015;26(8):726-9. doi: 10.3109/09537104.2014.983891. Epub 2014 Dec 30.

PMID:
25548984
2.

Elevated plasma levels and platelet-associated expression of the pro-thrombotic and pro-inflammatory protein, TNFSF14 (LIGHT), in sickle cell disease.

Garrido VT, Proença-Ferreira R, Dominical VM, Traina F, Bezerra MA, de Mello MR, Colella MP, Araújo AS, Saad ST, Costa FF, Conran N.

Br J Haematol. 2012 Sep;158(6):788-97. doi: 10.1111/j.1365-2141.2012.09218.x. Epub 2012 Jul 6.

PMID:
22775554
3.

A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.

Jakubowski JA, Zhou C, Jurcevic S, Winters KJ, Lachno DR, Frelinger AL 3rd, Gupta N, Howard J, Payne CD, Mant TG.

Thromb Res. 2014 Feb;133(2):190-5. doi: 10.1016/j.thromres.2013.12.008. Epub 2013 Dec 7.

PMID:
24368019
4.

Endothelial activation by platelets from sickle cell anemia patients.

Proença-Ferreira R, Brugnerotto AF, Garrido VT, Dominical VM, Vital DM, Ribeiro Mde F, dos Santos ME, Traina F, Olalla-Saad ST, Costa FF, Conran N.

PLoS One. 2014 Feb 13;9(2):e89012. doi: 10.1371/journal.pone.0089012. eCollection 2014.

5.

Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: Relation to cardiovascular complications.

Tantawy AA, Adly AA, Ismail EA, Habeeb NM, Farouk A.

Platelets. 2013;24(8):605-14. doi: 10.3109/09537104.2012.749397. Epub 2012 Dec 18.

PMID:
23249216
6.

Cytokines and plasma factors in sickle cell disease.

Brittain JE, Parise LV.

Curr Opin Hematol. 2007 Sep;14(5):438-43. Review.

PMID:
17934349
7.

Cytokine profile of sickle cell disease in Oman.

Pathare A, Al Kindi S, Alnaqdy AA, Daar S, Knox-Macaulay H, Dennison D.

Am J Hematol. 2004 Dec;77(4):323-8.

9.

Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.

Lanaro C, Franco-Penteado CF, Albuqueque DM, Saad ST, Conran N, Costa FF.

J Leukoc Biol. 2009 Feb;85(2):235-42. doi: 10.1189/jlb.0708445. Epub 2008 Nov 12.

PMID:
19004988
10.

Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel.

Ohno K, Tanaka H, Samata N, Jakubowski JA, Tomizawa A, Mizuno M, Sugidachi A.

Thromb Res. 2014 Oct;134(4):889-94. doi: 10.1016/j.thromres.2014.07.035. Epub 2014 Aug 6.

PMID:
25130912
11.

Increased adhesive and inflammatory properties in blood outgrowth endothelial cells from sickle cell anemia patients.

Sakamoto TM, Lanaro C, Ozelo MC, Garrido VT, Olalla-Saad ST, Conran N, Costa FF.

Microvasc Res. 2013 Nov;90:173-9. doi: 10.1016/j.mvr.2013.10.002. Epub 2013 Oct 18.

PMID:
24144783
12.

Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia.

Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A.

J Lab Clin Med. 1997 May;129(5):507-16.

PMID:
9142047
13.

Pattern of serum cytokine expression and T-cell subsets in sickle cell disease patients in vaso-occlusive crisis.

Musa BO, Onyemelukwe GC, Hambolu JO, Mamman AI, Isa AH.

Clin Vaccine Immunol. 2010 Apr;17(4):602-8. doi: 10.1128/CVI.00145-09. Epub 2010 Feb 3.

14.

Thrombosis and sickle cell disease.

De Franceschi L, Cappellini MD, Olivieri O.

Semin Thromb Hemost. 2011 Apr;37(3):226-36. doi: 10.1055/s-0031-1273087. Epub 2011 Mar 31. Review.

PMID:
21455857
15.

Plasma levels of TGF-β1 in homeostasis of the inflammation in sickle cell disease.

Torres Lde S, Okumura JV, da Silva DG, Belini Júnior É, de Oliveira RG, Mimura KK, Lobo CL, Oliani SM, Bonini Domingos CR.

Cytokine. 2016 Apr;80:18-25. doi: 10.1016/j.cyto.2016.02.012. Epub 2016 Feb 27.

PMID:
26928604
16.

Platelet activation in patients with sickle cell disease.

Wun T, Paglieroni T, Rangaswami A, Franklin PH, Welborn J, Cheung A, Tablin F.

Br J Haematol. 1998 Mar;100(4):741-9.

PMID:
9531343
17.

Abnormal expression of inflammatory genes in placentas of women with sickle cell anemia and sickle hemoglobin C disease.

Baptista LC, Costa ML, Ferreira R, Albuquerque DM, Lanaro C, Fertrin KY, Surita FG, Parpinelli MA, Costa FF, Melo MB.

Ann Hematol. 2016 Oct;95(11):1859-67. doi: 10.1007/s00277-016-2780-1. Epub 2016 Aug 22.

PMID:
27546026
18.

Increased adhesive properties of platelets in sickle cell disease: roles for alphaIIb beta3-mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity.

Proença-Ferreira R, Franco-Penteado CF, Traina F, Saad ST, Costa FF, Conran N.

Br J Haematol. 2010 Apr;149(2):280-8. doi: 10.1111/j.1365-2141.2010.08087.x. Epub 2010 Feb 5.

PMID:
20136824
19.

Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia.

Inwald DP, Kirkham FJ, Peters MJ, Lane R, Wade A, Evans JP, Klein NJ.

Br J Haematol. 2000 Nov;111(2):474-81. Erratum in: Br J Haematol 2001 Mar;112(4):1091.

PMID:
11122087
20.

ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.

Kim K, Li J, Barazia A, Tseng A, Youn SW, Abbadessa G, Yu Y, Schwartz B, Andrews RK, Gordeuk VR, Cho J.

Haematologica. 2017 Feb;102(2):246-259. doi: 10.3324/haematol.2016.151159. Epub 2016 Oct 6.

Supplemental Content

Support Center